Advances in the development of imaging probes and aggregation inhibitors for alpha-synuclein
文献类型：期刊论文
| 作者 | Xu, Ming-ming2; Ryan, Philip1,3,4; Rudrawar, Santosh1,3,4; Quinn, Ronald J.2; Zhang, Hai-yan5 ; Mellick, George D.2
|
| 刊名 | ACTA PHARMACOLOGICA SINICA
 |
| 出版日期 | 2020-04-01 |
| 卷号 | 41期号:4页码:483-498 |
| 关键词 | Parkinson's disease alpha-synuclein imaging probes aggregation inhibitors thioflavin-T mass spectrometry |
| ISSN号 | 1671-4083 |
| DOI | 10.1038/s41401-019-0304-y |
| 通讯作者 | Xu, Ming-ming(manny.xu@griffithuni.edu.au) ; Mellick, George D.(g.mellick@griffith.edu.au) |
| 英文摘要 | Abnormal protein aggregation has been linked to many neurodegenerative diseases, including Parkinson's disease (PD). The main pathological hallmark of PD is the formation of Lewy bodies (LBs) and Lewy neurites, both of which contain the presynaptic protein alpha-synuclein (alpha-syn). Under normal conditions, native alpha-syn exists in a soluble unfolded state but undergoes misfolding and aggregation into toxic aggregates under pathological conditions. Toxic alpha-syn species, especially oligomers, can cause oxidative stress, membrane penetration, synaptic and mitochondrial dysfunction, as well as other damage, leading to neuronal death and eventually neurodegeneration. Early diagnosis and treatments targeting PD pathogenesis are urgently needed. Given its critical role in PD, alpha-syn is an attractive target for the development of both diagnostic tools and effective therapeutics. This review summarizes the progress toward discovering imaging probes and aggregation inhibitors for alpha-syn. Relevant strategies and techniques in the discovery of alpha-syn-targeted drugs are also discussed. |
| WOS关键词 | SMALL-MOLECULE INHIBITORS ; PARKINSONS-DISEASE ; AMYLOID-BETA ; IN-VIVO ; NEURODEGENERATIVE DISEASES ; SYNAPTIC-TRANSMISSION ; FLUORESCENT DETECTION ; DIAGNOSTIC-CRITERIA ; CLINICAL-DIAGNOSIS ; OLIGOMER FORMATION |
| WOS研究方向 | Chemistry ; Pharmacology & Pharmacy |
| 语种 | 英语 |
| WOS记录号 | WOS:000523012600007 |
| 出版者 | NATURE PUBLISHING GROUP |
| 源URL | [http://119.78.100.183/handle/2S10ELR8/280904]  |
| 专题 | 中国科学院上海药物研究所 |
| 通讯作者 | Xu, Ming-ming; Mellick, George D. |
| 作者单位 | 1.Griffith Univ, Qual Use Med Network, Gold Coast, Qld 4222, Australia 2.Griffith Univ, Griffith Inst Drug Discovery, Brisbane Innovat Pk,Don Young Rd, Nathan, Qld 4111, Australia 3.Griffith Univ, Sch Pharm & Pharmacol, Gold Coast, Qld 4222, Australia 4.Griffith Univ, Menzies Hlth Inst Queensland, Gold Coast, Qld 4222, Australia 5.Chinese Acad Sci, Shanghai Inst Mat Med, CAS Key Lab Receptor Res, Shanghai 201203, Peoples R China |
| 推荐引用方式 GB/T 7714 | Xu, Ming-ming,Ryan, Philip,Rudrawar, Santosh,et al. Advances in the development of imaging probes and aggregation inhibitors for alpha-synuclein[J]. ACTA PHARMACOLOGICA SINICA,2020,41(4):483-498. |
| APA | Xu, Ming-ming,Ryan, Philip,Rudrawar, Santosh,Quinn, Ronald J.,Zhang, Hai-yan,&Mellick, George D..(2020).Advances in the development of imaging probes and aggregation inhibitors for alpha-synuclein.ACTA PHARMACOLOGICA SINICA,41(4),483-498. |
| MLA | Xu, Ming-ming,et al."Advances in the development of imaging probes and aggregation inhibitors for alpha-synuclein".ACTA PHARMACOLOGICA SINICA 41.4(2020):483-498. |
入库方式： OAI收割
来源：上海药物研究所
浏览0
下载0
收藏0
其他版本
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。